If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.50    2.50 (0.64%)
Bid:
385.00
Ask:
400.00
Spread: 15.00 (3.896%)
Market Cap: £188.39m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Approval for Wipes System from VAH in Germany

6 Jun 2011 07:00

RNS Number : 8688H
Tristel PLC
06 June 2011
 



 

 

Tristel plc

("Tristel" or "the Company")

AIM: TSTL

 

Approval for Wipes System from VAH in Germany

 

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received confirmation from the German Association for Applied Hygiene (Verbund fur Angewandte Hygiene or VAH), that its Wipes System has been included on the VAH list of approved disinfectants.

Tristel's patented Wipes System is widely used worldwide for the decontamination of the small and delicate medical instruments used in hospital departments such as ear, nose and throat (ENT), cardiology and ultrasound. The Wipes System was recently recognised by the ENT Societies in the United Kingdom and Italy as a preferred disinfection technique, and has also recently been approved by Australia's Therapeutic Goods Association.

Inclusion in the VAH list will enable Tristel to sell its Wipes System to public hospitals in Germany. Hitherto, the Wipes System has only been available to private hospitals and clinics. In the 8 month period that Tristel's German branch has been fully operational, the Wipes System has been adopted by 73 users in Germany. The VAH certification significantly expands the Wipes System's sales potential in Europe's largest hospital market. Germany has 2,100 hospitals and there are approximately 4,000 ENT consultants practising in the country. This compares to approximately 600 public and private hospitals combined in the United Kingdom where the Wipes System is used in over 70% of ENT clinics. Wipes System sales in the United Kingdom in the financial year ended 30 June 2010 were £1,449,000.

Paul Swinney, Chief Executive of Tristel, said: "The Wipes System is a unique product that is widely patented. With its inclusion in Germany's VAH list we have made another great stride in establishing the Wipes System as the gold standard for the types of medical instrument used in specialist hospital departments such as ENT and cardiology. Such specialist departments can be found in almost all hospitals worldwide, and are the areas specifically targeted as part of Tristel's international expansion plan."

 

 

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

finnCap

Geoff Nash / Charlotte Stranner (Corporate Finance)

Simon Starr (broking)

Tel: 020 7600 1658

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REABUGDLSXGBGBX
Date   Source Headline
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
31st Mar 20258:56 amRNSHolding(s) in Company
26th Mar 202510:30 amRNSDirector/PDMR Shareholding
18th Mar 20252:39 pmRNSHolding(s) in Company
24th Feb 20257:00 amRNSUnaudited Interim Results
7th Feb 20257:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20257:00 amRNSDirector Option Grant
13th Jan 20257:00 amRNSConfirmation of Interim Results
16th Dec 20242:45 pmRNSResult of AGM
16th Dec 20247:00 amRNSAGM Statement and Notice of Interim Results
22nd Nov 202410:30 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Nov 20241:32 pmRNSExercise of Share Options and Total Voting Rights
20th Nov 20248:47 amRNSExercise of Share Options and Total Voting Rights
28th Oct 20241:37 pmRNSExercise of Share Options and Total Voting Rights
21st Oct 20247:00 amRNSFinal Results
1st Oct 20247:00 amRNSNotice of Preliminary Results
20th Sep 20247:00 amRNSDirector/PDMR Shareholding
19th Sep 20241:13 pmRNSExercise of Share Options and Total Voting Rights
12th Sep 20247:00 amRNSFDA 510(k) submission for Tristel OPH
2nd Sep 20247:00 amRNSConfirmation of CEO Transition, Directorate Change
6th Aug 20243:32 pmRNSExercise of Share Options and Total Voting Rights
22nd Jul 20247:00 amRNSTrading Update
4th Jul 20243:43 pmRNSExercise of Share Options and Total Voting Rights
11th Jun 20245:48 pmRNSDirector/PDMR Shareholding
11th Jun 20243:50 pmRNSHolding(s) in Company
10th Jun 20247:00 amRNSAppointment of CEO
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.